Medulloblastoma: WHO 2021 and Beyond.
Cotter JA, Hawkins C.
Pediatr Dev Pathol. 2022 Jan-Feb;25(1):23-33. doi: 10.1177/10935266211018931.
[Medulloblastoma. Pathology].
Siegfried A, Delisle MB.
Neurochirurgie. 2021 Feb;67(1):28-38. doi: 10.1016/j.neuchi.2017.12.006. Epub 2018 Aug 14.
Primary leptomeningeal medulloblastoma: a case-based review.
Russo C, Scala MR, Spennato P, Nastro A, Errico ME, De Martino L, Cinalli G.
Childs Nerv Syst. 2022 Mar;38(3):527-536. doi: 10.1007/s00381-021-05435-x. Epub 2022 Jan 21.
Understanding medulloblastoma.
Quinlan A, Rizzolo D.
JAAPA. 2017 Oct;30(10):30-36. doi: 10.1097/01.JAA.0000524717.71084.50.
Medulloblastoma.
[No authors listed]
Nat Rev Dis Primers. 2019 Feb 14;5(1):12. doi: 10.1038/s41572-019-0067-2.
Management of high-risk medulloblastoma.
Bouffet E.
Neurochirurgie. 2021 Feb;67(1):61-68. doi: 10.1016/j.neuchi.2019.05.007. Epub 2019 Jun 20.
[Medulloblastoma].
Yamaguchi S, Fujimura M.
No Shinkei Geka. 2023 Sep;51(5):858-866. doi: 10.11477/mf.1436204827.
Targeting the medulloblastoma: a molecular-based approach.
Luzzi S, Giotta Lucifero A, Brambilla I, Semeria Mantelli S, Mosconi M, Foiadelli T, Savasta S.
Acta Biomed. 2020 Jun 30;91(7-S):79-100. doi: 10.23750/abm.v91i7-S.9958.
Medulloblastoma: Molecular Classification-Based Personal Therapeutics.
Archer TC, Mahoney EL, Pomeroy SL.
Neurotherapeutics. 2017 Apr;14(2):265-273. doi: 10.1007/s13311-017-0526-y.
Second-generation molecular subgrouping of medulloblastoma: an international meta-analysis of Group 3 and Group 4 subtypes.
Sharma T, Schwalbe EC, Williamson D, Sill M, Hovestadt V, Mynarek M, Rutkowski S, Robinson GW, Gajjar A, Cavalli F, Ramaswamy V, Taylor MD, Lindsey JC, Hill RM, Jäger N, Korshunov A, Hicks D, Bailey S, Kool M, Chavez L, Northcott PA, Pfister SM, Clifford SC.
Acta Neuropathol. 2019 Aug;138(2):309-326. doi: 10.1007/s00401-019-02020-0. Epub 2019 May 10.
